Traders should monitor the April 20, 2026 spin-off date and the execution of the $100M buyback, which could support ANAB stock. The market may re-rate Anaptys as a royalty vehicle, but execution risk around the separation and reliance on external partnerships (GSK, Vanda) remains.
Price Chart
Executive Summary
AnaptysBio is spinning off its biopharma operations into First Tracks Biotherapeutics, which secured $80 million in gross proceeds from a $145 million private placement. Concurrently, Anaptys announced a $100 million stock repurchase plan and a lean post-spin-off structure focused on managing royalty assets with minimal operating expenses.
Key Financial Metrics
Key Facts
- First Tracks Bio raised $80 million in gross proceeds from the sale of 5,791,478 shares at $13.81 per share in a private placement.
- The spin-off of First Tracks Bio is expected to close on April 20, 2026.
- Anaptys will retain ~$140–145 million in net cash and investments post-spin-off and operate with less than 10 FTEs and under $10M annual operating expenses.
- Anaptys announced a $100 million stock repurchase plan effective after March 31, 2026, expiring December 31, 2026.
- Susannah Gray, former CFO of Royalty Pharma, has been appointed to Anaptys’ board to support its royalty-focused strategy.
Financial Impact
$80 million raised by First Tracks Bio; $100 million buyback authorized by Anaptys; Anaptys to retain $140–145 million in cash and investments
Risk Factors
- Spin-off may not close as planned, delaying or altering capital return and structure.
- Anaptys’ future value depends entirely on third-party royalty performance (GSK, Vanda), introducing external execution risk.
- Limited transparency on how buyback will be executed; could be slow or market-dependent.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 press releases from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263788 |
| PRESS-RELEASE Data (Synthetic) | press-3263790 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 7w ago | Institutional Cluster | $56.02 $53.87 | ▼ −3.84% | ▼ −2.09% | $48.53 (−13.37%) |
Jun 29, 2026 13w ago | 144 | $67.50 $53.61 | ▲ +20.58% | ▲ +19.55% | $48.53 (+28.10%) |
Jun 29, 2026 13w ago | DEFA14A | $67.50 $53.61 | ▼ −20.58% | ▼ −19.55% | $48.53 (−28.10%) |
Jun 26, 2026 13w ago | 144 | $65.97 $54.15 | ▲ +17.92% | ▲ +17.64% | $48.53 (+26.44%) |
Jun 22, 2026 14w ago | 8-K | $59.43 $50.29 | ▼ −15.38% | ▼ −16.54% | $48.53 (−18.34%) |
Jun 17, 2026 15w ago | 144 | $57.51 $54.15 | ▲ +5.84% | ▲ +6.38% | $48.53 (+15.61%) |
Jun 15, 2026 15w ago | 144 | $57.61 $62.51 | ▼ −8.51% | ▼ −8.31% | $48.53 (+15.76%) |
Jun 11, 2026 16w ago | 144 | $56.07 $66.39 | ▼ −18.41% | ▼ −16.63% | $48.53 (+13.45%) |
Jun 10, 2026 16w ago | 144 | $54.24 $66.59 | ▼ −22.77% | ▼ −20.88% | $48.53 (+10.53%) |
Jun 8, 2026 16w ago | 144 | $51.63 $67.33 | ▼ −30.40% | ▼ −28.95% | $48.53 (+6.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access